Long-term safety of ADX-324 for hereditary angioedema
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hereditary angioedema (HAE) type I or II.
- You completed the previous study called ADX-324-301.
- You have access to emergency medicine to treat HAE attacks (like C1-inhibitor or a bradykinin receptor blocker).
- You did not have a bad reaction to the study drug in the previous study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study tests navenibart over a longer period to see if it continues to prevent swelling attacks in people with hereditary angioedema. It is for people who were already in a previous navenibart study.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study looks at how people with hereditary angioedema (HAE) are diagnosed and treated in Egypt. It may help doctors better understand and care for this condition.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.